Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 10/20 | 0.64 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | BRD4 | O60885 | 3/20 | 0.47 |
| ▸ | PRKACA | P17612 | 1/20 | 0.46 |
| ▸ | PRKACG | P22612 | 1/20 | 0.46 |
| ▸ | PRKACB | P22694 | 1/20 | 0.46 |
| ▸ | HSD17B3 | P37058 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | AMPD2 | Q01433 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27603646 | 0.86 | NOTUM (0.62) | NOTUMHTR1ADRD2HTR2ABRD4 | |
| SCHEMBL18407453 | 0.84 | NOTUM (0.53) | NOTUMHTR1ADRD2HTR2ABRD4 | |
| SCHEMBL9212320 | 0.83 | NOTUM (0.44) | NOTUMHTR1ADRD2HTR2APRKACA | |
| SCHEMBL14230009 | 0.83 | NOTUM (0.48) | NOTUMHTR1ADRD2HTR2APRKACA | |
| SCHEMBL7214558 | 0.83 | NOTUM (0.59) | NOTUMHTR1ADRD2HTR2ABRD4 | |
| SCHEMBL3956544 | 0.83 | NOTUM (0.59) | NOTUMHTR1ADRD2HTR2ABRD4 | |
| SCHEMBL3956526 | 0.83 | NOTUM (0.59) | NOTUMHTR1ADRD2HTR2ABRD4 | |
| SCHEMBL3956520 | 0.83 | NOTUM (0.59) | NOTUMHTR1ADRD2HTR2ABRD4 | |
| SCHEMBL12377535 | 0.83 | NOTUM (0.59) | NOTUMHTR1ADRD2HTR2ABRD4 | |
| SCHEMBL14200389 | 0.81 | NOTUM (0.46) | NOTUMHTR1ADRD2HTR2APRKACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110804008-A | 1, 3-disubstituted indoline derivative and preparation method thereof | 陕西科技大学 | 2020-02-18 | — | — | CN | disclosed |
| US-20120046283-A1 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | AFRAXIS INC. (US) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046283-A1 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | PAK2, PAK5, PAK6 | NOTUM 4244/4885HTR1A 96/4885DRD2 1446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.